Efficacy and Safety of Nilotinib Compared with Imatinib in Patients with Chronic Myeloid Leukemia

  • Thu, 1/28/10 - 2:34pm
  • 0 Comments
  • 598 reads

New Orleans—During a late breaking abstract session at the ASH conference, Giuseppe Saglio of the University of Turin, San Luigi Hospital, Orbassano, Italy, presented results of the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients) trial, a phase 3, randomized open-label, multicenter study that compared the efficacy and safety of 300 or 400 mg twice a day of nilotinib with 400 mg imatinib daily in patients with newly diagnosed Philadelphia chromosome chronic myeloid leukemia (Ph + CML) in chronic ph



Read the full story >>